Good results for ALS therapy

Israel’s Immunity Pharma had positive results from its Phase 2a human trial with IPL344 in amyotrophic lateral sclerosis (ALS) patients. Disease progression compared to placebo slowed by some 50% over 3 years. There were other positive indications and no serious adverse events.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *